Childhood and adolescent lymphoma in Spain: incidence and survival trends over 20 years

Abstract

Background

Lymphoma is the third most common malignancy in children (0–14 years) and the first in adolescents (15–19 years). This population-based study—the largest ever done in Spain—analyses incidence and survival of lymphomas among Spanish children and adolescents.

Patients and methods

1664 lymphoma cases (1983–2007) for incidence and 1030 for survival (1991–2005) followed until 31/12/2010, were provided by 11 cancer registries. Age-adjusted incidence rates (ASRw) to the world standard population were obtained; incidence trends were modelled using the Joinpoint programme, observed survival (OS) was estimated with Kaplan–Meier and trends tested with a log-rank test. Results are presented according to the International Classification of Childhood Cancer-3.

Results

In Spain, the ASRw_0–14 for lymphomas was 17.5 per 1.000.000 child-years and 50.0 the specific rate for adolescents. Overall incidence increased significantly during 1983–1997 with no increases thereafter. Patients over 9 years old showed significant rising trends for all subtypes, except for Burkitt lymphoma (BL) in adolescents. During 2001–2005 (age 0–19 years), 5-year OS was 94 (90–98), 73 (64–83) and 86 (78–94) for Hodgkin lymphoma (HL), non-Hodgkin lymphoma (NHL) and BL, respectively. No improvement in survival was found. The incidence in Spain was higher than overall European rates, but within the range of that in Southern Europe. Comparing OS in Spain 1991–1995 and 2001–2005 with results for Europe of the Automated Childhood Cancer Information System (ACCIS) (1988–1997) and the European cancer registry-based study on survival and care of cancer patients (EUROCARE) (2000–2007), it was similar for HL and lower for NHL and BL.

Conclusions

Systematic monitoring and analysis of lymphoma paediatric data would provide clinical and epidemiological information to improve the health care of these patients and the outcomes for these malignancies in Spain.

from Cancer via ola Kala on Inoreader https://ift.tt/2IvJHFK
via IFTTT